19 Jun 2019 12:00
Result of AGM
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Result of Annual General Meeting
Oxford, UK, and Cambridge, MA, US, 19 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that all resolutions proposed to shareholders at the Company’s Annual General Meeting (‘AGM’) held earlier today have been passed. The results of the proxy votes lodged in advance and at the meeting will be available shortly from the Investors section of Summit’s website, www.summitplc.com.
About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
Contacts
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking | ||
| Bryan Garnier & Co Limited (Joint Broker) | Tel: | +44 (0)20 7332 2500 |
| Phil Walker / Dominic Wilson | ||
| MSL Group (US) | Tel: | +1 781 684 6557 |
| Jon Siegal | summit@mslgroup.com | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Sue Stuart / | summit@consilium-comms.com | |
| Lindsey Neville |
-END-
SUMM.L (SUMM)